We are pleased to invite you to read the most viewed papers in 2023 in Cancers (ISSN: 2072-6694) on the topic of cancer immunology and immunotherapy. The paper list is as follows:

“Immunotherapy in Melanoma: Recent Advances and Future Directions”
by Andrew Knight, Lilit Karapetyan and John M. Kirkwood
Cancers 2023, 15(4), 1106; https://doi.org/10.3390/cancers15041106
Available online: https://www.mdpi.com/2072-6694/15/4/1106

“Immunotherapy for Triple-Negative Breast Cancer: Combination Strategies to Improve Outcome”
by Liying Li, Fan Zhang, Zhenyu Liu and Zhimin Fan
Cancers 2023, 15(1), 321; https://doi.org/10.3390/cancers15010321
Available online: https://www.mdpi.com/2072-6694/15/1/321

“CAR-T: What Is Next?”
by Yi-Ju Chen, Bams Abila and Yasser Mostafa Kamel
Cancers 2023, 15(3), 663; https://doi.org/10.3390/cancers15030663
Available online: https://www.mdpi.com/2072-6694/15/3/663

“mRNA-Lipid Nanoparticle (LNP) Delivery of Humanized EpCAM-CD3 Bispecific Antibody Significantly Blocks Colorectal Cancer Tumor Growth”
by Vita Golubovskaya, John Sienkiewicz, Jinying Sun, Yanwei Huang, Liang Hu, Hua Zhou, Hizkia Harto, Shirley Xu, Robert Berahovich, Walter Bodmer et al.
Cancers 2023, 15(10), 2860; https://doi.org/10.3390/cancers15102860
Available online: https://www.mdpi.com/2072-6694/15/10/2860

“Emerging Targeted Therapies for HER2-Positive Breast Cancer”
by María Florencia Mercogliano, Sofía Bruni, Florencia Luciana Mauro and Roxana Schillaci
Cancers 2023, 15(7), 1987; https://doi.org/10.3390/cancers15071987
Available online: https://www.mdpi.com/2072-6694/15/7/1987

“Beyond CTLA-4 and PD-1 Inhibition: Novel Immune Checkpoint Molecules for Melanoma Treatment”
by Dimitrios C. Ziogas, Charalampos Theocharopoulos, Panagiotis-Petros Lialios, Dimitra Foteinou, Ioannis-Alexios Koumprentziotis, Georgios Xynos and Helen Gogas
Cancers 2023, 15(10), 2718; https://doi.org/10.3390/cancers15102718
Available online: https://www.mdpi.com/2072-6694/15/10/2718

“Ready for Prime Time? Dendritic Cells in High-Grade Gliomas”
by Claire A. Conarroe and Timothy N. J. Bullock
Cancers 2023, 15(11), 2902; https://doi.org/10.3390/cancers15112902
Available online: https://www.mdpi.com/2072-6694/15/11/2902

“Predictive Biomarkers for Checkpoint Inhibitor Immune-Related Adverse Events”
by Iñigo Les, Mireia Martínez, Inés Pérez-Francisco, María Cabero, Lucía Teijeira, Virginia Arrazubi, Nuria Torrego, Ana Campillo-Calatayud, Iñaki Elejalde, Grazyna Kochan et al.
Cancers 2023, 15(5), 1629; https://doi.org/10.3390/cancers15051629
Available online: https://www.mdpi.com/2072-6694/15/5/1629

“Immunotherapy for Peritoneal Carcinomatosis: Challenges and Prospective Outcomes”
by Mefotse Saha Cyrelle Ornella, Narayanasamy Badrinath, Kyeong-Ae Kim, Jung Hee Kim, Euna Cho, Tae-Ho Hwang and Jae-Joon Kim
Cancers 2023, 15(8), 2383; https://doi.org/10.3390/cancers15082383
Available online: https://www.mdpi.com/2072-6694/15/8/2383

“Lenalidomide in Multiple Myeloma: Review of Resistance Mechanisms, Current Treatment Strategies and Future Perspectives”
by Piotr Kulig, Sławomir Milczarek, Estera Bakinowska, Laura Szalewska, Bartłomiej Baumert and Bogusław Machaliński
Cancers 2023, 15(3), 963; https://doi.org/10.3390/cancers15030963
Available online: https://www.mdpi.com/2072-6694/15/3/963

You are welcome to submit relevant papers to the journal Cancers.

Cancers Editorial Office